Literature DB >> 1652099

Negative and positive selection of antigen-specific cytotoxic T lymphocytes affected by the alpha 3 domain of MHC I molecules.

C J Aldrich1, R E Hammer, S Jones-Youngblood, U Koszinowski, L Hood, I Stroynowski, J Forman.   

Abstract

The alpha 1 and alpha 2 domains of major histocompatibility complex (MHC) class I molecules function in the binding and presentation of foreign peptides to the T-cell antigen receptor and control both negative and positive selection of the T-cell repertoire. Although the alpha 3 domain of class I is not involved in peptide binding, it does interact with the T-cell accessory molecule, CD8. CD8 is important in the selection of T cells as anti-CD8 antibody injected into perinatal mice interferes with this process. We previously used a hybrid class I molecule with the alpha 1/alpha 2 domains from Ld and the alpha 3 domain from Q7b and showed that this molecule binds an Ld-restricted peptide but does not interact with CD8-dependent cytotoxic T lymphocytes. Expression of this molecule in transgenic mice fails to negatively select a subpopulation of anti-Ld cytotoxic T lymphocytes. In addition, positive selection of virus-specific Ld-restricted cytotoxic T lymphocytes does not occur. We conclude that besides the alpha 1/alpha 2 domains of class I, the alpha 3 domain plays an important part in both positive and negative selection of antigen-specific cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652099     DOI: 10.1038/352718a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  17 in total

Review 1.  The role of CD4 in regulating homeostasis of T helper cells.

Authors:  Rolf König; Xiaoli Shen; Rosario Maroto; Timothy L Denning
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Insights into T-cell development from studies using transgenic and knockout mice.

Authors:  M A Basson; R Zamoyska
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

3.  Disruption of the CD4-major histocompatibility complex class II interaction blocks the development of CD4(+) T cells in vivo.

Authors:  J M Riberdy; E Mostaghel; C Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis.

Authors:  C R Brown; C A Hunter; R G Estes; E Beckmann; J Forman; C David; J S Remington; R McLeod
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

5.  A heterodimer of HEB and an E12-related protein interacts with the CD4 enhancer and regulates its activity in T-cell lines.

Authors:  S Sawada; D R Littman
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

6.  The role of charge and multiple faces of the CD8 alpha/alpha homodimer in binding to major histocompatibility complex class I molecules: support for a bivalent model.

Authors:  P A Giblin; D J Leahy; J Mennone; P B Kavathas
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

7.  Identification and characterization of an Alu-containing, T-cell-specific enhancer located in the last intron of the human CD8 alpha gene.

Authors:  J E Hambor; J Mennone; M E Coon; J H Hanke; P Kavathas
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

8.  Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4.

Authors:  N Killeen; S Sawada; D R Littman
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

9.  Thy-1 triggers mouse thymocyte apoptosis through a bcl-2-resistant mechanism.

Authors:  A O Hueber; G Raposo; M Pierres; H T He
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

10.  Reconstitution of the subclass-specific expression of CD4 in thymocytes and peripheral T cells of transgenic mice: identification of a human CD4 enhancer.

Authors:  M D Blum; G T Wong; K M Higgins; M J Sunshine; E Lacy
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.